At ProMetic, we believe that our long term relationship with internationally renowned scientists and opinion leaders reflects our common goal: creation and validation of opportunities.
Our Advisory Committees are comprised of experts in the fields of biopharmaceutical, clinical study, biotechnology and bioprocess. These distinguished members provide ProMetic with significant guidance for appropriate strategies in research and development, clinics, regulations and commercialization related to our exclusive platform technology and portfolio of proprietary therapeutic products.
We work together to enable innovation, capture commercial opportunities and build a valuable future for our products and technology.
Julie Beaudet, MD
Oncologist, Maisonneuve-Rosemont Hospital
Norman Muirhead, M.D.
Professor, Nephrology at London Health Sciences Centres – University Hospital
Allen R. Nissenson, MD, F.A.C.P., F.A.S.N.
Professor of Medicine, Associate Dean for Special Projects and Director of the Dialysis Program
David Geffen School of Medicine at UCLA
Vincent Pichette, M.D.
Associate Professor of Medicine at the University of Montréal
Researcher, Nephrology at Maisonneuve-Rosemont Hospital
Denis-Claude Roy, MD
Hematologist, Associate Professor of Medicine at the University of Montréal
Research Director at Maisonneuve-Rosemont Hospital
John C. Curling, Ph.D.
Peter Edwardson, Ph.D.
Dr. Peter Edwardson was formerly Vice-President, Medical Technologies for ProMetic BioSciences Ltd
David J. Stewart, Ph.D.
Director of Meetings and Courses,
Cold Spring Harbor Laboratory, NY, USA.
Ruben G. Carbonell, Ph.D.
Director, William R. Kenan Junior Institute for Engineering Technology and Science,
North Carolina University.
Robert G. Rohwer, Ph.D.
Director, Molecular Neurovirology Laboratory,
Veteran’s Affairs Medical Center and
associate Professor of Neurology,
University of Maryland School of Medicine